Donepezil and memantine are the most common drugs used for Alzheimer's disease. Their
low effectiveness could partly be explained by genetic factors. Thus, we aim to identify …

Donepezil (DNP) is the first-line drug used for Alzheimer's disease (AD). However, the
therapeutic response rate of patients to DNP varies from 20 to 60%. The main reason for the …

Purpose This study aims to evaluate the influence of genetic polymorphisms of CYP2D6,
CYP3A5, ABCB1, and APOE genes and nongenetic factors on steady-state plasma …

Introduction Alzheimer disease (AD) is the most common cause of dementia and is
considered one of the main causes of disability and dependence affecting quality of life in …

Aim: The impact of CYP2D6 and CYP3A4 polymorphism on the steady-state plasma
concentrations and therapeutic outcome of donepezil monotherapy and combination …

Background Differential responses to donepezil treatment in patients with Alzheimer's
disease (AD) have been observed in clinical practice. It remains controversial whether, and …

With the aging population and its rapidly increasing prevalence, dementia has become an
important public health concern in developed and developing countries. To date, the …

Donepezil is the leading compound for the treatment of Alzheimer's disease (AD) in more
than 50 countries. As compared with other conventional acetylcholinesterase inhibitors …

Purpose Donepezil, a drug frequently used to treat dementia, is mainly metabolized by
cytochrome P450 2D6 (CYP2D6). This study investigated the relationships between …

Purpose The aim of our study was to evaluate the impact of CYP3A4, CYP3A5, and ABCB1
polymorphisms on donepezil disposition and clinical outcome. Methods Fifty-four Italian …